Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD920 for venous leg ulcers
ACTRN12608000060347Phase 3Terminated
- Sponsor
- Aus Bio
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MD920 in stasis ulcer (2 arms), sponsored by Aus Bio. Primary endpoint: Percentage reduction in wound size. Started Mar 2008; status: terminated.
02
Drugs
MD920
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on ACTRN12608000060347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000060347.